Kuros Biosciences AG said Harry Welten will step down as CFO on Feb. 1, 2018, to focus on his board roles and part-time CFO functions in privately held companies.
Welten, who will remain on Kuros' board, will be replaced by Michael Grau as CFO, effective Feb. 1, 2018.
Previously, Grau served as CFO of Proteros Biostructures, a biotech company focusing on enabling lead discovery; Correvio, a Geneva-based hospital specialty pharmaceutical company; and Endosense, a Geneva-based private medical technology company.
